| VBWG Reports |
| VBWG Reports - September 2004 |
|
| October 26, 2004 |
In this issue of VBWG ReportsTM our editors report on presentations at recent VBWG national meetings that address important findings in areas that impact treatment for cardiovascular disease: the biochemistry of atrial fibrillation; the role of insulin resistance in heart failure; interactions between low-density lipoprotein (LDL) and the renin-angiotensin-aldosterone (RAAS) system; and the impact of peripheral arterial disease on cardiovascular risk.
| Biochemical insights into atrial fibrillation | | David G. Harrison, MD | | Emory University School of Medicine |
| Heart failure as an insulin resistance state: Role of b-blockade | | Thomas D. Giles, MD | | Louisiana State University Health Sciences Center |
| LDL and the RAAS: The role of oxidative stress and vascular inflammation | | Robert A. Vogel, MD | | University of Maryland School of Medicine |
| PAD as a CV risk marker: New data from HOPE | | Jeffrey L. Probstfield, MD | | University of Washington, Seattle | |
The content expresses the views of the editors and does not necessarily reflect the views or recommendations of the University of Florida College of Medicine or the publisher. The reader is advised to consult the full prescribing information for all medications prior to use.
VBWG Reports is provided as a service to the medical profession through educational grants from AstraZeneca, King Pharmaceuticals Inc, Pfizer Inc,and Wyeth Pharmaceuticals.
©2004 MEDCONSM. All rights reserved. |
|
Resources